Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome
- 1 November 2002
- journal article
- research article
- Published by Wiley in American Journal Of Medical Genetics Part B-Neuropsychiatric Genetics
- Vol. 117B (1), 57-60
- https://doi.org/10.1002/ajmg.b.10025
Abstract
Our previous study has suggested that the TaqI A polymorphism of dopamine D2 receptor gene (DRD2) is associated with the predisposition to neuroleptic malignant syndrome (NMS). However, the specificity of this polymorphism as a predictor of NMS dose not seem to be sufficient enough. Meanwhile, it has been shown that the non‐carriers of Del allele of the −141C Ins/Del polymorphism in the promoter region of DRD2 have lower dopamine D2 receptor in the brain than the carriers. In addition, dopamine D3 receptor gene has a Ser9Gly polymorphism, which may alter the receptor function. The present study examined the association between these three polymorphisms and the development of NMS to investigate if a combination of these polymorphisms could increase the specificity as markers for NMS. The subjects were 17 psychiatric patients who had developed NMS (13 patients with schizophrenia, 3 with major depression, and 1 with dementia of the Alzheimer's type) and 163 schizophrenic patients who had never developed this syndrome. The frequency of the A1 allele was significantly (P = 0.012) higher in the patients who had developed NMS (59%) than in the patients who had not (35%). The proportion of the A1 carriers was significantly (P = 0.003) higher in the patients with NMS (16/17: 94%) than in those without the syndrome (93/163: 57%). However, no significant differences were found in the allele and genotype frequencies of the other two polymorphisms between the two groups. The present study suggests that only the TaqI A polymorphism is at least partly useful as a predictor of NMS, but the −141 C Ins/Del and Ser9Gly polymorphisms are not.Keywords
This publication has 18 references indexed in Scilit:
- Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in SchizophreniaNeuropsychopharmacology, 1999
- Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteersMolecular Psychiatry, 1999
- D2 dopamine receptor polymorphism and brain regional glucose metabolismAmerican Journal of Medical Genetics, 1997
- A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophreniaHuman Molecular Genetics, 1997
- Proposed Schizophrenia-Related Gene Polymorphism: Expression of the Ser9Gly Mutant Human Dopamine D3Receptor with the Semliki Forest Virus SystemBiochemical and Biophysical Research Communications, 1996
- PCR detection of the TaqA RFLP at the DRD2 locusHuman Molecular Genetics, 1993
- Treatment of neuroleptic malignant syndrome with levodopaHuman Psychopharmacology: Clinical and Experimental, 1992
- Crossover reaction between haloperidol and amoxapine for NMSThe British Journal of Psychiatry, 1991
- Allelic Association of the D2 Dopamine Receptor Gene With Receptor-Binding Characteristics in Alcoholism or Gene ismArchives of General Psychiatry, 1991
- Is the Predisposition to Neuroleptic Malignant Syndrome Genetically Transmitted?The British Journal of Psychiatry, 1991